References
- Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol. 1995;25:1056–12. doi:https://doi.org/10.1002/eji.1830250430.
- Wegmann DR, Norbury-Glaser M, Insulin-specific DD. T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol. 1994;24:1853–57. doi:https://doi.org/10.1002/eji.1830240820.
- Jasinski JM, Yu L, Nakayama M, Li MM, Lipes MA, Eisenbarth GS, Liu E. Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes. 2006;55:1978–84. doi:https://doi.org/10.2337/db06-0058.
- Stadinski B, Kappler J, Eisenbarth GS. Molecular targeting of islet autoantigens. Immunity. 2010;32:446–56. doi:https://doi.org/10.1016/j.immuni.2010.04.008.
- Yi W, Seth NP, Martillotti T, Wucherpfennig KW, Sant’Angelo DB, Denzin LK. Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J C linInvest. 2010;120:1324–36. doi:https://doi.org/10.1172/JCI40220.
- Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005;435:220–23. doi:https://doi.org/10.1038/nature03523.
- Yang J, Chow IT, Sosinowski T, Torres-Chinn N, Greenbaum CJ, James EA, Kappler JW, Davidson HW, Kwok WW. Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc Natl Acad Sci U S A. 2014;111:14840–45.
- Wang Y, Sosinowski T, Novikov A, Crawford F, White J, Jin N, Liu Z, Zou J, Neau D, Davidson HW, et al. How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes. Sci Immunol. 2019;4(34) :eaav7517. doi: https://doi.org/10.1126/sciimmunol.aav7517.
- Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, et al. Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes. Diabetes. 2017;66(3):722–34. doi:https://doi.org/10.2337/db16-1025.
- Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084–92. doi:https://doi.org/10.2337/db07-1331.
- Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, Teyton L. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science. 2000;288:505–11. doi:https://doi.org/10.1126/science.288.5465.505.
- Suri A, Vidavsky I, van der DK, Kanagawa O, Gross ML, Unanue ER. APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket. J Immunol. 2002;168:1235–43. doi:https://doi.org/10.4049/jimmunol.168.3.1235.
- Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol. 2010;11:350–54.
- Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med. 2011;208:2375–83. doi:https://doi.org/10.1084/jem.20111502.
- Gioia L, Holt M, Costanzo A, Sharma S, Abe B, Kain L, Nakayama M, Wan X, Su A, Mathews C, et al. Position beta57 of I-A(g7) controls early anti-insulin responses in NOD mice, linking an MHC susceptibility allele to type 1 diabetes onset. Sci Immunol. 2019;4(38):eaaw6329. doi:https://doi.org/10.1126/sciimmunol.aaw6329.
- Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A. 2010;107:10978–83. doi:https://doi.org/10.1073/pnas.1006545107.
- Crawford F, Stadinski B, Jin N, Michels A, Nakayama M, Pratt P, Marrack P, Eisenbarth G, Kappler JW. Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci U S A. 2011;108:16729–34. doi:https://doi.org/10.1073/pnas.1113954108.
- Zhang L, Crawford F, Yu L, Michels A, Nakayama M, Davidson HW, Kappler JW, Eisenbarth GS. Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci U S A. 2014;111:2656–61. doi:https://doi.org/10.1073/pnas.1323436111.
- Wang Y, Sosinowski T, Novikov A, Crawford F, Neau DB, Yang J, Kwok WW, Marrack P, Kappler JW, Dai S, et al. C-terminal modification of the insulin B:11–23 peptide creates superagonists in mouse and human type 1 diabetes. Proc Natl Acad Sci U S A. 2018;115(1):162–67. doi:https://doi.org/10.1073/pnas.1716527115.
- Oi VT, Jones PP, Goding JW, Herzenberg LA, Herzenberg LA. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol. 1978;81:115–20.
- Boitard C, Bendelac A, Richard MF, Carnaud C, Bach JF. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc Natl Acad Sci U S A. 1988;85:9719–23. doi:https://doi.org/10.1073/pnas.85.24.9719.
- Delong T, Baker RL, He J, Barbour G, Bradley B, Haskins K. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes. 2012;61:3239–46. doi:https://doi.org/10.2337/db12-0112.
- Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol. 2010;11:225–31. doi:https://doi.org/10.1038/ni.1844.
- Spanier JA, Frederick DR, Taylor JJ, Heffernan JR, Kotov DI, Martinov T, Osum KC, Ruggiero JL, Rust BJ, Landry SJ, et al. Efficient generation of monoclonal antibodies against peptide in the context of MHCII using magnetic enrichment. Nat Commun. 2016;7(1):11804. doi:https://doi.org/10.1038/ncomms11804.
- Yamano S, Atkinson JC, Baum BJ, Fox PC. Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol. 1999;92:265–75. doi:https://doi.org/10.1006/clim.1999.4759.
- Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 2006;54:2300–05. doi:https://doi.org/10.1002/art.21945.
- Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS. Early expression of anti-insulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A. 2000;97:1701–06. doi:https://doi.org/10.1073/pnas.040556697.
- Pearson JA, Wong FS, Wen L. The importance of the non-obese diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun. 2016;66:76–88.
- Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, et al. A preclinical consortium approach for assessing the efficacy of combined anti-CD3 Plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD Mice. Diabetes. 2016;65:1310–16. doi:https://doi.org/10.2337/db15-0492.
- Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes. 1990;39:933–37. doi:https://doi.org/10.2337/diab.39.8.933.
- Roep BO, Wheeler DCS, Peakman M. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 2019;7:65–74. doi:https://doi.org/10.1016/S2213-8587(18)30109-8.
- Howell SL. The mechanism of insulin secretion. Diabetologia. 1984;26:319–27. doi:https://doi.org/10.1007/BF00266030.
- Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol. 2008;20:111–18. doi:https://doi.org/10.1016/j.coi.2007.11.005.
- Wicker LS, Clark J, Fraser HI, Garner VE, Gonzalez-Munoz A, Healy B, Howlett S, Hunter K, Rainbow D, Rosa RL, et al. Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun. 2005;25(Suppl):29–33.
- Mannering SI, Di Carluccio AR, Elso CM. Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes. Diabetologia. 2019;62:351–56. doi:https://doi.org/10.1007/s00125-018-4760-6.
- Melli K, Friedman RS, Martin AE, Finger EB, Miao G, Szot GL, Krummel MF, Tang Q. Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J Immunol. 2009;182:2590–600. doi:https://doi.org/10.4049/jimmunol.0803543.
- Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–88.
- Davidson HW, Zhang L. Immune therapies for autoimmune diabetes targeting pathogenic peptideMHC complexes. J Mol Cell Biol. 2020. doi:https://doi.org/10.1093/jmcb/mjaa037.
- Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol. 1988;18:313–16. doi:https://doi.org/10.1002/eji.1830180221.
- Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs. 2017;9:767–73. doi:https://doi.org/10.1080/19420862.2017.1323159.
- Beers SA, Glennie MJ, White AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127:1097–101. doi:https://doi.org/10.1182/blood-2015-09-625343.
- Levisetti MG, Suri A, Petzold SJ, Unanue ER. The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J Immunol. 2007;178:6051–57. doi:https://doi.org/10.4049/jimmunol.178.10.6051.
- Nakayama M, Castoe T, Sosinowski T, He X, Johnson K, Haskins K, Vignali DAA, Gapin L, Pollock D, Eisenbarth GS, et al. Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes. 2012;61:857–65. doi:https://doi.org/10.2337/db11-1113.
- Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K, Roep BO, Gottlieb PA, Atkinson MA, Eisenbarth GS, et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol. 2011;187(11):5921–30. doi:https://doi.org/10.4049/jimmunol.1100746.
- Haskins K, Portas M, Bergman B, Lafferty K, Bradley B. Pancreatic islet-specific T cell clones from nonobese diabetic mice. Proc Natl Acad Sci USA. 1989;86:8000–04. doi:https://doi.org/10.1073/pnas.86.20.8000.
- Zhang L, Jasinski JM, Kobayashi M, Davenport B, Johnson K, Davidson H, Nakayama M, Haskins K, Eisenbarth GS. Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 alpha chains. J Autoimmun. 2009;33:42–49. doi:https://doi.org/10.1016/j.jaut.2009.02.003.
- Shulman M, Wilde CD, Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature. 1978;276:269–70. doi:https://doi.org/10.1038/276269a0.
- Talbot WS, Swyryd EA, Hogness DS. Drosophila tissues with different metamorphic responses to ecdysone express different ecdysone receptor isoforms. Cell. 1993;73:1323–37. doi:https://doi.org/10.1016/0092-8674(93)90359-X.
- Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, et al. Differential effects of EGFL6 on tumor versus wound angiogenesis. Cell Rep. 2017;21:2785–95. doi:https://doi.org/10.1016/j.celrep.2017.11.020.
- Zhang L, Stadinski BD, Michels A, Kappler JW, Eisenbarth GS. Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice. Diabetes Metab Res Rev. 2011;27:784–89. doi:https://doi.org/10.1002/dmrr.1252.
- Leiter EH. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol. 2001;Chapter 15:Unit 15 9.